- Home
- DNA vs ALT Comparison
DNA vs ALT Comparison
Compare DNA & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNA
- ALT
- Stock Information
- Founded
- DNA 2008
- ALT 1997
- Country
- DNA United States
- ALT United States
- Employees
- DNA N/A
- ALT N/A
- Industry
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- DNA Health Care
- ALT Health Care
- Exchange
- DNA Nasdaq
- ALT Nasdaq
- Market Cap
- DNA 466.4M
- ALT 472.3M
- IPO Year
- DNA N/A
- ALT N/A
- Fundamental
- Price
- DNA $7.08
- ALT $5.29
- Analyst Decision
- DNA Sell
- ALT Strong Buy
- Analyst Count
- DNA 3
- ALT 7
- Target Price
- DNA $9.67
- ALT $21.00
- AVG Volume (30 Days)
- DNA 1.1M
- ALT 2.5M
- Earning Date
- DNA 05-06-2025
- ALT 05-13-2025
- Dividend Yield
- DNA N/A
- ALT N/A
- EPS Growth
- DNA N/A
- ALT N/A
- EPS
- DNA N/A
- ALT N/A
- Revenue
- DNA $237,417,000.00
- ALT $20,000.00
- Revenue This Year
- DNA N/A
- ALT $4,108.32
- Revenue Next Year
- DNA $15.26
- ALT $3,900.06
- P/E Ratio
- DNA N/A
- ALT N/A
- Revenue Growth
- DNA 13.76
- ALT N/A
- 52 Week Low
- DNA $5.00
- ALT $3.55
- 52 Week High
- DNA $23.29
- ALT $11.16
- Technical
- Relative Strength Index (RSI)
- DNA 45.07
- ALT 46.53
- Support Level
- DNA $6.90
- ALT $5.38
- Resistance Level
- DNA $7.62
- ALT $5.74
- Average True Range (ATR)
- DNA 0.48
- ALT 0.33
- MACD
- DNA -0.08
- ALT -0.06
- Stochastic Oscillator
- DNA 20.00
- ALT 1.18
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
About ALT Altimmune Inc.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.